Objective: To investigate the clinical e cacy and safety of hyperthermic intraperitoneal chemotherapy H(IPEC) in the treatment of recurrent nephroblastoma in children. Study Design: Randomised controlled trial. Place and Duration of Study: Department of Oncology, Baoding Children's Hospital, from August 2018 to November 2021. Methodology: Sixty children with recurrent nephroblastoma treated byHIPEC in the Department of Surgical Oncology were analysed and divided into group A and group B, according to di erent perfused drugs. Additionally, 30 children without a history ofHIPEC were selected as the control group (group C). The changes in routine blood indices, albumin, and hepatic and renal function of the three groups were observed before and after treatment. The clinical e cacy, frequency of adverse reactions, as well as 6-month and 1-year tumour recurrence in the three groups were compared. Results: The e cacy in groups A and B was signi cantly higher than that in group pC<(0.05). Changes in routine blood indices, albumin, and hepatic and renal function showed no statistically signi cant di erences among the three groups during each observation period after treatment (all p>0.05). No signi cant di erences were found in the incidence of adverse reactions among the three groups during treatment (allp>0.05). Six months after treatment, the tumour recurrence rate presented no signi cant di erences among the three groups. However, at 12-months after treatment, the recurrence rate in groups A and B was lower than that in group C (p <0.05). Conclusion: For children with recurrent nephroblastoma, intraoperativeHIPEC has little impact on the body, can signi cantly improve the e ectiveness and reduce the recurrence rate, and does not increase the adverse reactions.